These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 9177842)

  • 41. Lowering of pI by acylation improves the renal uptake of 99mTc-labeled anti-Tac dsFv: effect of different acylating reagents.
    Kim I; Kobayashi H; Yoo TM; Kim MK; Le N; Han ES; Wang QC; Pastan I; Carrasquillo JA; Paik CH
    Nucl Med Biol; 2002 Nov; 29(8):795-801. PubMed ID: 12453588
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolism of Tac (IL2Ralpha): physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding.
    Junghans RP; Waldmann TA
    J Exp Med; 1996 Apr; 183(4):1587-602. PubMed ID: 8666917
    [TBL] [Abstract][Full Text] [Related]  

  • 43. (68) Ga-labeled Ciprofloxacin Conjugates as Radiotracers for Targeting Bacterial Infection.
    Satpati D; Arjun C; Krishnamohan R; Samuel G; Banerjee S
    Chem Biol Drug Des; 2016 May; 87(5):680-6. PubMed ID: 26647765
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reagents for astatination of biomolecules. 6. An intact antibody conjugated with a maleimido-closo-decaborate(2-) reagent via sulfhydryl groups had considerably higher kidney concentrations than the same antibody conjugated with an isothiocyanato-closo-decaborate(2-) reagent via lysine amines.
    Wilbur DS; Chyan MK; Nakamae H; Chen Y; Hamlin DK; Santos EB; Kornblit BT; Sandmaier BM
    Bioconjug Chem; 2012 Mar; 23(3):409-20. PubMed ID: 22296587
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolism of radiometal-labeled proteins and peptides: what are the real radiopharmaceuticals in vivo?
    Anderson CJ
    Cancer Biother Radiopharm; 2001 Dec; 16(6):451-5. PubMed ID: 11789022
    [No Abstract]   [Full Text] [Related]  

  • 46. New Radiolabeled Exendin Analogues Show Reduced Renal Retention.
    Joosten L; Frielink C; Jansen TJP; Lobeek D; Andreae F; Konijnenberg M; Heskamp S; Gotthardt M; Brom M
    Mol Pharm; 2023 Jul; 20(7):3519-3528. PubMed ID: 37265006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Copper-64-Labeled Antibody Fragments for Immuno-PET/Radioimmunotherapy with Low Renal Radioactivity Levels and Amplified Tumor-Kidney Ratios.
    Suzuki H; Kise S; Kaizuka Y; Watanabe R; Sugawa T; Furukawa T; Fujii H; Uehara T
    ACS Omega; 2021 Aug; 6(33):21556-21562. PubMed ID: 34471758
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Toxicological Studies of 212Pb Intravenously or Intraperitoneally Injected into Mice for a Phase 1 Trial.
    Milenic DE; Molinolo AA; Solivella MS; Banaga E; Torgue J; Besnainou S; Brechbiel MW; Baidoo KE
    Pharmaceuticals (Basel); 2015 Jul; 8(3):416-34. PubMed ID: 26213947
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activatable fluorescent cys-diabody conjugated with indocyanine green derivative: consideration of fluorescent catabolite kinetics on molecular imaging.
    Sano K; Nakajima T; Ali T; Bartlett DW; Wu AM; Kim I; Paik CH; Choyke PL; Kobayashi H
    J Biomed Opt; 2013 Oct; 18(10):101304. PubMed ID: 23752742
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dendrimer nanoscaffolds for potential theranostics of prostate cancer with a focus on radiochemistry.
    Lo ST; Kumar A; Hsieh JT; Sun X
    Mol Pharm; 2013 Mar; 10(3):793-812. PubMed ID: 23294202
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reagents for astatination of biomolecules. 5. Evaluation of hydrazone linkers in (211)At- and (125)I-labeled closo-decaborate(2-) conjugates of Fab' as a means of decreasing kidney retention.
    Wilbur DS; Chyan MK; Hamlin DK; Nguyen H; Vessella RL
    Bioconjug Chem; 2011 Jun; 22(6):1089-102. PubMed ID: 21513347
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Improved biodistribution of 125I-labeled anti-Tac disulfide-stabilized Fv fragment by blocking its binding to the alpha subunit of the interleukin 2 receptor in the circulation with preinjected humanized anti-Tac IgG.
    Kobayashi H; Yoo TM; Drumm D; Kim MK; Sun BF; Le N; Webber KO; Pastan I; Waldmann TA; Paik CH; Carrasquillo JA
    Cancer Res; 1997 May; 57(10):1955-61. PubMed ID: 9157991
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Strategies to reduce renal radioactivity levels of antibody fragments.
    Arano Y
    Q J Nucl Med; 1998 Dec; 42(4):262-70. PubMed ID: 9973841
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biodistribution and catabolism of Ga-67-labeled anti-Tac dsFv fragment.
    Wu C; Jagoda E; Brechbiel M; Webber KO; Pastan I; Gansow O; Eckelman WC
    Bioconjug Chem; 1997; 8(3):365-9. PubMed ID: 9177842
    [TBL] [Abstract][Full Text] [Related]  

  • 56. L-lysine effectively blocks renal uptake of 125I- or 99mTc-labeled anti-Tac disulfide-stabilized Fv fragment.
    Kobayashi H; Yoo TM; Kim IS; Kim MK; Le N; Webber KO; Pastan I; Paik CH; Eckelman WC; Carrasquillo JA
    Cancer Res; 1996 Aug; 56(16):3788-95. PubMed ID: 8706025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Biodistribution of 18F- and 125I-labeled anti-Tac disulfide-stabilized Fv fragments in nude mice with interleukin 2 alpha receptor-positive tumor xenografts.
    Choi CW; Lang L; Lee JT; Webber KO; Yoo TM; Chang HK; Le N; Jagoda E; Paik CH; Pastan I
    Cancer Res; 1995 Nov; 55(22):5323-9. PubMed ID: 7585595
    [TBL] [Abstract][Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.